INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of 1

Complete if Known				
Application Number:	10/772,809			
Filing Date:	February 5, 2004			
First Named Inventor:	Joel Bernstein			
Group Art Unit:	1617			
Confirmation Number:	5946			
Examiner Name:	Claytor, Deirdre Renee			
Attorney Docket Number:	41957-102748			

U.S. PATENT DOCUMENTS							
		U.S. Patent Document					
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	ВА	6,342,530	B1	Darko	Jan. 29, 2002		
	ВВ	2004/019111	A1	Jerussi et al.	Jan. 29, 2004		

FOREIGN PATENT DOCUMENTS								
	T T	Foreign Patent Document		nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	ВС	wo	99/59598	Α	Dalhousie University	Nov. 25, 1999		
	BD	wo	00/50025	Α	Bioglan Laboratories Ltd.	Aug. 31, 2000		
	BE	WO	02/26020	А	The Brigham and Women's Hospital, Inc.	Apr. 4, 2002		
	BF	СН	693 586	A5	Roche Consumer Health, AG	Oct. 31, 2003		Х

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (boc magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			
	ВG	Copy of Supplementary European Search Report issued in EP 05 71 2627 (2008).		
				<u> </u>
				İ

CHDS01 AOM 500218v1

_		· · · · · · · · · · · · · · · · · · ·		
Γ	EXAMINER		DATE CONSIDERED	
L				

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).